Analytically and Clinically Validated

The DISCERN™ Test

Skin is a window
to the brain

At SYNAPS Dx, we utilize a groundbreaking yet remarkably simple method for diagnosing Alzheimer’s disease. Our process requires only a crumb-sized skin sample, which can be easily collected during a quick and minimally invasive procedure.

The skin sample undergoes sophisticated biochemical analysis in our labs. By examining specific protein markers in the skin cells, DISCERN™ identifies the presence of Alzheimer's disease with over 95% accuracy. This advanced biomarker technology allows us to distinguish Alzheimer’s from other forms of dementia effectively.

the science

Learn More About Our Research

At SYNAPS Dx, we're dedicated to transparency in Alzheimer's diagnostics, offering an extensive suite of scientific resources. Our publications, whitepapers, and assay notes detail the robust science behind our DISCERN™ test.

Discover how our diagnostics are shaping Alzheimer’s care—visit our website to explore our scientific contributions.
Read our scientific papers
THE THREE BIOMARKERS
The three biomarkers
Morphometric Imaging
In a clinical trial with the Morphometric assay, patients with autopsy-confirmed AD could be accurately distinguished from patients with non-AD dementias and age-matched controls.

Sensitivity: 100%, Specificity 100%
PKCε Assay
In a clinical trial with the PKCε assay, patients with autopsy-confirmed AD could be accurately distinguished from patients with non-AD dementias and age-matched controls.

Sensitivity: 100%, Specificity 96%
AD-Index
In a clinical trial with the AD – Index assay, patients with autopsy-confirmed AD could be accurately distinguished from patients with non-AD dementias and age-matched controls.

Sensitivity 97%, Specificity 86%
Learn More about discern™
Explore the Future of Alzheimer’s Diagnostics
Learn more about DISCERN™ on our dedicated website. See how our precision diagnostics are changing lives and advancing care.
Visit the DISCERN™ Website